CPT vs DMAC · P/E 104, rev $7.1M vs $157.4M cap
Camden Property Trust (CPT) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
Camden Property Trust (CPT) is a reit - residential company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported CPT revenue for 2024-12-31 was $7.1M. Net income was $170.8M. Revenue was up 106.8% from 2023-12-31 to 2024-12-31. CPT currently screens at market cap $12.11B and trailing P/E 104.0.
DMAC does not have a complete income-statement cache yet.
CPT currently screens at market cap $12.11B and trailing P/E 104.0. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the CPT and DMAC stock pages for the full models.
Not investment advice.